The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors
Open accessAbstract
Neurofibromatosis type 1 (NF1) patients develop benign neurofibromas and malignant peripheral nerve sheath tumors (MPNST). These incurable peripheral nerve tumors result from loss of NF1 tumor suppressor gene function, causing hyperactive Ras signaling. Activated Ras controls numerous downstream effectors, but specific pathways mediating the effects of hyperactive Ras in NF1 tumors are unknown. We performed cross-species transcriptome analyses of mouse and human neurofibromas and MPNSTs and identified global negative feedback of genes that regulate Ras/Raf/MEK/ERK signaling in both species. Nonetheless, ERK activation was sustained in mouse and human neurofibromas and MPNST. We used a highly selective pharmacological inhibitor of MEK, PD0325901, to test whether sustained Ras/Raf/MEK/ERK signaling contributes to neurofibroma growth in a neurofibromatosis mouse model (Nf1(fl/fl);Dhh-Cre) or in NF1 patient MPNST cell xenografts. PD0325901 treatment reduced aberrantly proliferating cells in neurofibroma and MPNST, prolonged survival of mice implanted with human MPNST cells, and shrank neurofibromas in more than 80% of mice tested. Our data demonstrate that deregulated Ras/ERK signaling is critical for the growth of NF1 peripheral nerve tumors and provide a strong rationale for testing MEK inhibitors in NF1 clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 1×
“In addition, NF1 mutations are frequently found in tumor types other than neurofibroma and MPNST, including glioblastoma (57), lung adenocarcinoma (58), and ovarian cancer (59).”
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
Senescence in premalignant tumours
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., et al. (2005) · Nature · doi:10.1038/436642a · Cited by 1,482 · cited 1×
“However, in benign tumors, Ras signaling can alternatively be associated with oncogene-induced senescence (15, 16), and evidence supports a role for cellular senescence in NF1 dermal neurofibromas (17).”
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
Malignant peripheral nerve sheath tumours in neurofibromatosis 1
Evans, D. G. R., Baser, M. E., McGaughran, J., Sharif, S., Howard, E., & Moran, A. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.5.311 · Cited by 1,282
Targeting the mitogen-activated protein kinase cascade to treat cancer
Sebolt-Leopold, J. S., & Herrera, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1503 · Cited by 1,108
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients
Basu, T. N., Gutmann, D. H., Fletcher, J. A., Glover, T. W., Collins, F. S., & Downward, J. (1992) · Nature · doi:10.1038/356713a0 · Cited by 668
Neurofibromas in NF1: Schwann Cell Origin and Role of Tumor Environment
Zhu, Y., Ghosh, P., Charnay, P., Burns, D. K., & Parada, L. F. (2002) · Science · doi:10.1126/science.1068452 · Cited by 633
Pratilas, C. A., Taylor, B. S., Ye, Q., Viale, A., Sander, C., Solit, D. B., & Rosen, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900780106 · Cited by 614
The NF1 tumor suppressor critically regulates TSC2 and mTOR
Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., & Cichowski, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503224102 · Cited by 601
DeClue, J. E., Papageorge, A. G., Fletcher, J. A., Diehl, S. R., Ratner, N., Vass, W. C., & Lowy, D. R. (1992) · Cell · doi:10.1016/0092-8674(92)90407-4 · Cited by 580 · cited 2×
“Despite transcriptional upregulation of genes that repress Raf/MEK/ERK signaling, and consistent with neurofibroma (11) and MPNST (12, 13) cells having elevated levels of Ras-GTP, activation of the downstream effector ERK was maintained in neurofibromas and MPNSTs, as elevated levels of…”
Self-citationA negative feedback signaling network underlies oncogene-induced senescence
Courtois-Cox, S., Genther Williams, S. M., Reczek, E. E., Johnson, B. W., McGillicuddy, L. T., Johannessen, C. M., Hollstein, P. E., MacCollin, M., & Cichowski, K. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.003 · Cited by 501
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis.
Sweet-Cordero, A., Mukherjee, S., Subramanian, A., You, H., Roix, J. J., Ladd-Acosta, C., Mesirov, J., Golub, T. R., & Jacks, T. (2005) · Nature Genetics · doi:10.1038/ng1490 · Cited by 414
Carli, M., Ferrari, A., Mattke, A., Zanetti, I., Casanova, M., Bisogno, G., Cecchetto, G., Alaggio, R., De Sio, L., Koscielniak, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.4886 · Cited by 371
Nf1-Dependent Tumors Require a Microenvironment Containing Nf1+/−- and c-kit-Dependent Bone Marrow
Yang, F.-C., Ingram, D. A., Chen, S., Zhu, Y., Yuan, J., Li, X., Yang, X., Knowles, S., Horn, W., Li, Y., et al. (2008) · Cell · doi:10.1016/j.cell.2008.08.041 · Cited by 364
Therapeutic Strategies for Targeting Ras Proteins
Gysin, S., Salt, M., Young, A., & McCormick, F. (2011) · Genes & Cancer · doi:10.1177/1947601911412376 · Cited by 323
Mechanisms of drug inhibition of signalling molecules
Sebolt-Leopold, J. S., & English, J. M. (2006) · Nature · doi:10.1038/nature04874 · Cited by 304
Sos, M. L., Fischer, S., Ullrich, R., Peifer, M., Heuckmann, J. M., Koker, M., Heynck, S., Stückrath, I., Weiss, J., Fischer, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907325106 · Cited by 254
LoRusso, P. M., Krishnamurthi, S. S., Rinehart, J. J., Nabell, L. M., Malburg, L., Chapman, P. B., DePrimo, S. E., Bentivegna, S., Wilner, K. D., Tan, W., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1883 · Cited by 252
Haura, E. B., Ricart, A. D., Larson, T. G., Stella, P. J., Bazhenova, L., Miller, V. A., Cohen, R. B., Eisenberg, P. D., Selaru, P., Wilner, K. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1920 · Cited by 237
Wu, J., Williams, J. P., Rizvi, T. A., Kordich, J. J., Witte, D., Meijer, D., Stemmer-Rachamimov, A. O., Cancelas, J. A., & Ratner, N. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.027 · Cited by 236
Self-citationMiller, S. J., Rangwala, F., Williams, J., Ackerman, P., Kong, S., Jegga, A. G., Kaiser, S., Aronow, B. J., Frahm, S., Kluwe, L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3330 · Cited by 211
Self-citationTumor microenvironment and neurofibromatosis type I: connecting the GAPs
Le, L. Q., & Parada, L. F. (2007) · Oncogene · doi:10.1038/sj.onc.1210261 · Cited by 203
NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight
Dombi, E., Solomon, J., Gillespie, A. J., Fox, E., Balis, F. M., Patronas, N., Korf, B. R., Babovic-Vuksanovic, D., Packer, R. J., Belasco, J., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000250332.89420.e6 · Cited by 202
Self-citationNarita, M., & Lowe, S. W. (2005) · Nature Medicine · doi:10.1038/nm0905-920 · Cited by 174
Induction of Abnormal Proliferation by Nonmyelinating Schwann Cells Triggers Neurofibroma Formation
Zheng, H., Chang, L., Patel, N., Yang, J., Lowe, L., Burns, D. K., & Zhu, Y. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.002 · Cited by 170
Nf1 has an essential role in endothelial cells
Gitler, A. D., Zhu, Y., Ismat, F. A., Lu, M. M., Yamauchi, Y., Parada, L. F., & Epstein, J. A. (2003) · Nature Genetics · doi:10.1038/ng1059 · Cited by 168
The Loss of Nf1 Transiently Promotes Self-Renewal but Not Tumorigenesis by Neural Crest Stem Cells
Joseph, N. M., Mosher, J. T., Buchstaller, J., Snider, P., McKeever, P. E., Lim, M., Conway, S. J., Parada, L. F., Zhu, Y., & Morrison, S. J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.003 · Cited by 167
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras
Lauchle, J., Kim, D. S., Le, D., Akagi, K., Crone, M., Krisman, K., Warner, K., Bonifas, J. M., Li, Q., Coakley, K. M., et al. (2009) · Nature · doi:10.1038/nature08279 · Cited by 164
Masica, D. L., & Karchin, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0180 · Cited by 159
Sherman, L. S., Atit, R. P., Rosenbaum, T., Cox, A. D., & Ratner, N. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001702200 · Cited by 151
Self-citationHow does the Schwann cell lineage form tumors in NF1?
Carroll, S. L., & Ratner, N. (2008) · Glia · doi:10.1002/glia.20776 · Cited by 148
Self-citationPathophysiology of Neurofibromatosis Type 1
Theos, A. J., & Korf, B. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-11-200606060-00010 · Cited by 146
Johansson, G., Mahller, Y. Y., Collins, M. H., Kim, M., Nobukuni, T., Perentesis, J. P., Cripe, T. P., Lane, H. A., Kozma, S. C., Thomas, G., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2335 · Cited by 144
Self-citationMiller, S. J., Jessen, W. J., Mehta, T. S., Hardiman, A., Sites, E. R., Kaiser, S., Jegga, A. G., Li, H., Upadhyaya, M., Giovannini, M., et al. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900027 · Cited by 142
Self-citationKatz, D., Lazar, A. J., & Lev, D. C. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001227 · Cited by 139
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice
Chang, T. Y., Krisman, K., Theobald, E. H., Xu, J., Akutagawa, J., Lauchle, J., Kogan, S. C., Braun, B. S., & Shannon, K. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63193 · Cited by 130
Brown, A. P., Carlson, T., Loi, C., & Graziano, M. J. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0323-5 · Cited by 127
McCormick, F. P. (1995) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(95)90053-5 · Cited by 116
Ciuffreda, L., Bufalo, D. D., Desideri, M., Sanza, C. D., Stoppacciaro, A., Ricciardi, M. R., Chiaretti, S., Tavolaro, S., Benassi, B., Bellacosa, A., et al. (2009) · Neoplasia · doi:10.1593/neo.09398 · Cited by 111
McCaughan, J. A., Holloway, S., Davidson, R., & Lam, W. W. K. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2006.048140 · Cited by 108
Mahller, Y. Y., Vaikunth, S. S., Ripberger, M. C., Baird, W. H., Saeki, Y., Cancelas, J. A., Crombleholme, T. M., & Cripe, T. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2734 · Cited by 94
Self-citationA MEK Inhibitor Abrogates Myeloproliferative Disease in Kras Mutant Mice
Lyubynska, N., Gorman, M. F., Lauchle, J., Hong, W. X., Akutagawa, J., Shannon, K., & Braun, B. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001069 · Cited by 92
Solomon, J. M., Warren, K. E., Dombi, E., Patronas, N. J., & Widemann, B. C. (2004) · Computerized Medical Imaging and Graphics · doi:10.1016/j.compmedimag.2004.03.002 · Cited by 90
Self-citationLiu, C., Cripe, T. P., & Kim, M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.127 · Cited by 89
Self-citationBoasberg, P. D., Redfern, C. H., Daniels, G. A., Bodkin, D., Garrett, C. R., & Ricart, A. D. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1620-1 · Cited by 76
Patel, A. V., Eaves, D. W., Jessen, W. J., Rizvi, T. A., Ecsedy, J., Qian, M. G., Aronow, B. J., Perentesis, J. P., Serra, E., Cripe, T. P., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1072 · Cited by 72
Self-citationGioeli, D. G., Wunderlich, W., Sebolt, J. S., Bekiranov, S., Wulfkuhle, J. D., Petricoin, E. F., Conaway, M. C., & Weber, M. J. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1033 · Cited by 71
Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children.
Friedrich, R. E., Hartmann, M., & Mautner, V.-F. (2007) · PubMed · Cited by 69
Wu, J., Dombi, E., Jousma, E., Dunn, R. S., Lindquist, D. M., Schnell, B. M., Kim, M., Kim, A., Widemann, B. C., Cripe, T. P., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23015 · Cited by 66
Self-citationRaedt, T. D., Maertens, O., Chmara, M., Brems, H., Heyns, I., Sciot, R., Majounie, E., Upadhyaya, M., Schepper, S. D., Speleman, F., et al. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20353 · Cited by 65
Bollag, G. E., & McCormick, F. P. (1992) · Nature · doi:10.1038/356663a0 · Cited by 62
Phase I trial of pegylated interferon-α-2b in young patients with plexiform neurofibromas
Jakacki, R. I., Dombi, E., Potter, D. M., Goldman, S., Allen, J. C., Pollack, I. F., & Widemann, B. C. (2011) · Neurology · doi:10.1212/wnl.0b013e318207b031 · Cited by 57
Self-citationRal Overactivation in Malignant Peripheral Nerve Sheath Tumors
Bodempudi, V., Yamoutpoor, F., Pan, W., Dudek, A. Z., Esfandyari, T., Piedra, M., Babovic‐Vuksanovic, D., Woo, R. A., Mautner, V. F., Kluwe, L., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01153-08 · Cited by 55
Costello and cardio‐facio‐cutaneous syndromes: Moving toward clinical trials in RASopathies
Rauen, K. A., Banerjee, A., Bishop, W. R., Lauchle, J., McCormick, F. P., McMahon, M., Mélèse, T., Münster, P. N., Nadaf, S., Packer, R. J., et al. (2011) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30294 · Cited by 52
Mahller, Y. Y., Rangwala, F. A., Ratner, N., & Cripe, T. P. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20565 · Cited by 42
Self-citationBack to the future: Proceedings from the 2010 NF Conference
Huson, S., Acosta, M. T., Belzberg, A. J., Bernards, A., Chernoff, J., Cichowski, K. M., Evans, D. G., Ferner, R. E., Giovannini, M., Korf, B. R., et al. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33804 · Cited by 32
Self-citation
Cited by
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Compromised MAPK signaling in human diseases: an update
Kim, E. K., & Choi, E.-J. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1472-2 · Cited by 1,020
Gutmann, D. H., Ferner, R. E., Listernick, R. H., Korf, B. R., Wolters, P. L., & Johnson, K. J. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.4 · Cited by 862
Selumetinib in Children with Inoperable Plexiform Neurofibromas
Gross, A. M., Wolters, P. L., Dombi, E., Baldwin, A., Whitcomb, P., Fisher, M. J., Weiss, B., Kim, A., Bornhorst, M., Shah, A. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912735 · Cited by 726
Self-citationActivity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
Dombi, E., Baldwin, A., Marcus, L. J., Fisher, M. J., Weiss, B., Kim, A., Whitcomb, P., Martin, S., Aschbacher-Smith, L. E., Rizvi, T. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605943 · Cited by 682
Self-citation
Metadata
- Authors
- Jessen, W. J., Miller, S. J., Jousma, E., Wu, J., Rizvi, T. A., Brundage, M. E., Eaves, D., Widemann, B., Kim, M.-O., Dombi, E., Sabo, J., Hardiman Dudley, A., Niwa-Kawakita, M., Page, G. P., Giovannini, M., Aronow, B. J., Cripe, T. P., & Ratner, N.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-12-10
- Volume
- 123
- Issue
- 1
- Pages
- 340-347
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1976009942
- Cited by
- 334
- References
- 60
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.